Piper Sandler Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $33

Piper Sandler analyst Matt O'Brien has upgraded Tandem Diabetes Care (NASDAQ: TNDM) from Neutral to Overweight. The price target for the stock has been raised from $21 to $33.